Stromal Cell-Derived Factor (SDF)-1-Pretreated Bone Marrow Mesenchymal Stem Cells (BMSCs) Ameliorates Acute Kidney Injury in Mice

Abstract

To explore the effects of stromal cell-derived factor (SDF-1) pretreatment of bone marrow mesenchymal stem cells (BMSCs) on acute kidney injury (AKI) in mice. BMSCs were cultured and treated with SDF-1 to detect osteogenic and adipogenic ability. Cisplatin (20 mg/kg) was used to establish AKI model and then divided into blank group, control group 2 (BMSCs injection), and experimental group (intraperitoneal injection of BMSCs treated with SDF-1 (80 ng/ml)) followed by analysis of serum cytokines (Toll like receptor 4 (TLR4), tumor necrosis factor-α (TNF-α), and interleukine-6 (IL-6)) by enzyme linked immunosorbent assay (ELISA). In cultured BMSCs, positive rates of CD29, CD44, CD45, and CD11b were 98.2%, 97.6%, 2.5% and 2.1%, respectively. When the concentration of SDF-1 was within 80 ng/mL, the chemotaxis and proliferation ability was dose-dependent (p < 0.05). SDF-1 pretreatment did not affect BMSCs adipogenic and osteogenic abilities. The creatinine and serum cytokines (TLR4, TNF-α, and IL-6) level in experimental group showed statistical significance (p < 0.05). At 24 h, thrombosis and tubular dilatation in the mesangial region of control group 2 and experimental group under light microscope were similar without difference of inflammatory cell infiltration and fibrosis. At 72 h, the glomerular mesangium widened in control group 2 with focal segmental sclerosis, renal tubules dilated, and protein casts and inflammatory cell infiltration and fibrosis. Experimental group showed a small amount of cell proliferation in the glomerular mesangium with few inflammatory cell infiltration and fibrosis. SDF-1 can enhance the migration and proliferation activity of BMSCs, reduce extracellular matrix precipitation, improve renal fibrosis, and alleviate AKI.